Xiao Jun Huang

Summary

Country: China

Publications

  1. ncbi A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy
    Xiaojun Huang
    Peking University People s Hospital, Peking University Institute of Hematology, Beijing, China
    Future Microbiol 7:201-9. 2012
  2. ncbi Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    X J Huang
    Institute of Hematology, Peking University, People Hospital, Beijing, China
    Bone Marrow Transplant 36:343-8. 2005
  3. ncbi Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies
    Huang Xiao-Jun
    Peking University People s Hospital, Institute of Hematology, Beijing 100044, China
    Clin Cancer Res 15:4777-83. 2009
  4. ncbi Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies
    X J Huang
    Peking University Institute of Hematology, People s Hospital, Beijing, PRC
    Bone Marrow Transplant 38:291-7. 2006
  5. ncbi Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions
    Xiao Jun Huang
    Peking University Institute of Hematology, People s Hospital, 42 Bei Li Shi Lu Beijing, 100044, China
    Transpl Immunol 17:193-7. 2007
  6. ncbi Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation
    Xiao Jun Huang
    Institute of Hematology, People s Hospital, Peking University, Beijing, China
    Haematologica 92:414-7. 2007
  7. ncbi Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect
    X J Huang
    Peking University People s Hospital, Peking University Institute of Hematology, Beijing, People s Republic of China
    Bone Marrow Transplant 44:309-16. 2009
  8. ncbi Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation
    Xiao Jun Huang
    Institute of Hematology, Peking University, Beijing, People s Republic of China
    Biol Blood Marrow Transplant 15:257-65. 2009
  9. ncbi Immune-related late-onset hemorrhagic cystitis post allogeneic hematopoietic stem cell transplantation
    Xiao Jun Huang
    Institute of Hematology, Peking University People s Hospital, Beijing, China
    Chin Med J (Engl) 121:1766-9. 2008
  10. ncbi Treating donor mice with rhIL-11 and rhG-CSF promotes transplant-tolerance and preserves the effects of GVL after allogeneic bone marrow transplantation
    Xiao Jun Huang
    Peking University People s Hospital and Peking University Institute of Hematology, no 11, XiZhiMen South Street, Beijing 100044, China
    Leuk Res 33:123-8. 2009

Collaborators

Detail Information

Publications107 found, 100 shown here

  1. ncbi A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy
    Xiaojun Huang
    Peking University People s Hospital, Peking University Institute of Hematology, Beijing, China
    Future Microbiol 7:201-9. 2012
    ..Although initial studies have described its use in treating various fungal infections, its efficacy and safety in patients with invasive fungal infections remains to be further confirmed...
  2. ncbi Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    X J Huang
    Institute of Hematology, Peking University, People Hospital, Beijing, China
    Bone Marrow Transplant 36:343-8. 2005
    ..6% in liver, 75% in mouth and 100% in the eye, among all enrolled patients. Side effects were minor. Short-term, low-dose MTX is a tolerable and an effective regimen for patients with aGVHD, cGVHD or post-DLI GVHD after allo-HSCT...
  3. ncbi Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies
    Huang Xiao-Jun
    Peking University People s Hospital, Institute of Hematology, Beijing 100044, China
    Clin Cancer Res 15:4777-83. 2009
    ....
  4. ncbi Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies
    X J Huang
    Peking University Institute of Hematology, People s Hospital, Beijing, PRC
    Bone Marrow Transplant 38:291-7. 2006
    ..0017). The results require confirmation and show that G-BM combined with PBSC from haploidentical family donors, without in vitro TCD, may be used as a good source of stem cells for allo-HSCT...
  5. ncbi Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions
    Xiao Jun Huang
    Peking University Institute of Hematology, People s Hospital, 42 Bei Li Shi Lu Beijing, 100044, China
    Transpl Immunol 17:193-7. 2007
    ..The immunological characteristics of T cells in G-BM and G-PB mixed in vitro in different proportions were investigated...
  6. ncbi Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation
    Xiao Jun Huang
    Institute of Hematology, People s Hospital, Peking University, Beijing, China
    Haematologica 92:414-7. 2007
    ..GVHD prophylaxis reduced the incidence of acute GVHD. Our primary data showed that G-CSF-primed DLI with GVHD prophylaxis was a potentially effective therapeutic option for patients who relapsed after haploidentical HSCT...
  7. ncbi Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect
    X J Huang
    Peking University People s Hospital, Peking University Institute of Hematology, Beijing, People s Republic of China
    Bone Marrow Transplant 44:309-16. 2009
    ..Using immunosuppressive agents for 2-4 weeks may reduce DLI-associated acute GVHD without influencing relapse and survival after G-CSF-primed DLI...
  8. ncbi Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation
    Xiao Jun Huang
    Institute of Hematology, Peking University, Beijing, People s Republic of China
    Biol Blood Marrow Transplant 15:257-65. 2009
    ..001, relative risk [RR], 95% confidence interval [CI]: 2.94[1.535-5.631]) and the occurrence of aGVHD of grades 3 and 4 (P= .004). HLA-mismatched/haploidentical HSCT was feasible with unmanipulated blood and bone marrow harvest...
  9. ncbi Immune-related late-onset hemorrhagic cystitis post allogeneic hematopoietic stem cell transplantation
    Xiao Jun Huang
    Institute of Hematology, Peking University People s Hospital, Beijing, China
    Chin Med J (Engl) 121:1766-9. 2008
    ..The aim of this study was to analyze the alloimmune aetiology in the pathogenesis of LOHC post allogeneic hematopoietic stem cell transplantation (HSCT)...
  10. ncbi Treating donor mice with rhIL-11 and rhG-CSF promotes transplant-tolerance and preserves the effects of GVL after allogeneic bone marrow transplantation
    Xiao Jun Huang
    Peking University People s Hospital and Peking University Institute of Hematology, no 11, XiZhiMen South Street, Beijing 100044, China
    Leuk Res 33:123-8. 2009
    ..The 30 d leukemia-free survival improved significantly in F (70%) compared to C (0%), D (40%), and E (20%) (P<0.01). Thus, treating donor mice with rhIL-11 and rhG-CSF promoted transplant-tolerance and recipient survival...
  11. ncbi HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase
    Huang Xiao-Jun
    Peking University Institute of Hematology, People s Hospital, Beijing, China
    Ann Med 40:444-55. 2008
    ..Recently, we developed an effective method for haploidentical allo-HSCT achieving comparable outcomes to HLA-identical transplantation...
  12. ncbi Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia--feasibility and safety study
    Xiao Jun Huang
    Peking University Institute of Hematology, People s Hospital, Beijing, 100044, People s Republic of China
    J Clin Immunol 28:390-7. 2008
    ..We retrospectively evaluated the feasibility and safety of a modified prophylactic donor lymphocytes infusion (DLI) approach in advanced leukemia...
  13. ncbi Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia
    Xiao Jun Huang
    Institute of Hematology, People s Hospital, Peking University, No 11 Xizhimen South Street, 100044 Beijing, People s Republic of China
    J Clin Immunol 28:276-83. 2008
    ..3 +/- 9.6% at 3 years. Chronic GVHD was associated with a lower relapse rate and higher probability of LFS. Prophylactic-modified DLI is feasible in patients with advanced leukemia to prevent relapse after HLA-mismatched HCT...
  14. ncbi A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease
    Xiao Jun Huang
    Peking University Institute of Hematology, People s Hospital, Beijing 100044, China
    Chin Med J (Engl) 117:1778-85. 2004
    ..We developed a new technique for HLA mismatched allogeneic HSCT using G-CSF primed bone marrow plus G-CSF-mobilized peripheral blood stem cells without ex vivo T cell depletion...
  15. ncbi Current status of haploidentical stem cell transplantation for leukemia
    Xiao Jun Huang
    Institute of Hematology, People s Hospital, Peking University, no 11, Xi Zhi Men South Street, Beijing, 10044, PR China
    J Hematol Oncol 1:27. 2008
    ....
  16. ncbi [A novel approach to HLA-mismatched transplantation]
    Xiao Jun Huang
    Institute of Hematology, Peking University People s Hospital, Beijing 100044, China
    Beijing Da Xue Xue Bao 36:229-33. 2004
    ..To investigate the new methods of human leukocyte antigen (HLA) mismatched transplantation in patients with hematologic malignancies...
  17. ncbi Unmanipulated HLA-mismatched/haploidentical blood and marrow hematopoietic stem cell transplantation
    Xiao Jun Huang
    Peking University People s Hospital, Peking University Institute of Hematology, Beijing, People s Republic of China
    Biol Blood Marrow Transplant 17:197-204. 2011
    ....
  18. ncbi [The therapeutic effects of FLAG regime for refractory and relapsing acute leukemia]
    Xiao Jun Huang
    Institute of Hematology and People Hospital, Peking University, Beijing 100044, China
    Zhonghua Nei Ke Za Zhi 42:417-9. 2003
    ..To investigate the therapeutic effects of FLAG regimen for refractory and relapsing acute leukemia...
  19. ncbi Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients
    Xiao Jun Huang
    Peking University People s Hospital, Peking University Institute of Hematology, No 11 Xizhimen South Street, Beijing, China
    Best Pract Res Clin Haematol 24:351-8. 2011
    ..Further elucidation of the underlying mechanisms that govern leukemia stem cell escape from immunosurveillance after haploidentical HSCT may broaden our understanding and lead to therapies that control relapse...
  20. ncbi In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor
    Huang Xiao Jun
    Peking University, Institute of Hematology, People s Hospital, 42 Bei Li Shi Lu Beijing 100044, PR of China
    Haematologica 89:1517-24. 2004
    ..This study evaluated the function of T cells and the quantities of immunological cells of G-BM...
  21. ncbi Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia
    Xiao Jun Huang
    Peking University People s Hospital, Peking University Hematology Institute, Beijing, People s Republic of China
    Biol Blood Marrow Transplant 17:649-56. 2011
    ..Individualized intervention based on the post-HSCT BCR-ABL transcript level can decrease relapse and increase LFS of patients with CML after HLA-identical sibling HSCT...
  22. ncbi Combined transplantation of G-CSF primed allogeneic bone marrow cells and peripheral blood stem cells in treatment of severe aplastic anemia
    Xiao-jun Huang
    Peking University Institute of Hematology, People's Hospital, Beijing 100044, China
    Chin Med J (Engl) 117:604-7. 2004
  23. ncbi Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation
    Dao Pei Lu
    Peking University Institute of Hematology, 11 Xizhimen South Street, Beijing 100044, China
    Blood 107:3065-73. 2006
    ..In summary, HCT performed with related HLA-mismatched donors is a feasible approach with acceptable outcomes...
  24. ncbi Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison
    Yu Wang
    Peking University People s Hospital, Institute of Hematology, Beijing, People s Republic of China
    Biol Blood Marrow Transplant 17:821-30. 2011
    ..048) patients. Our comparisons suggest that HID transplants can achieve a stronger graft-versus-leukemia (GVL) effect than ISD for high-risk acute leukemia patients...
  25. ncbi Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients
    Xiang Yu Zhao
    Peking University Institute of Hematology, Peking University People s Hospital, Beijing, China
    Eur J Haematol 78:338-46. 2007
    ....
  26. ncbi The impact of CD34+ cell dose on platelet engraftment in pediatric patients following unmanipulated haploidentical blood and marrow transplantation
    Ying Jun Chang
    Peking University People s Hospital, Peking University Institute of Hematology, Beijing, China
    Pediatr Blood Cancer 53:1100-6. 2009
    ..The aim of this study was to investigate the effects of donor and recipient characteristics on hematopoietic recovery in pediatric patients following unmanipulated haploidentical transplantation...
  27. ncbi [Allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia]
    Yu Wang
    Institute of Hematology, People s Hospital, Peking University, Beijing 100044, China
    Zhonghua Nei Ke Za Zhi 46:903-6. 2007
    ..To retrospectively analyze the results of a consecutive series of 90 refractory/relapsed acute leukemia (AL) patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT) in our center...
  28. ncbi The impact of graft composition on clinical outcomes in pediatric patients undergoing unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation
    Dai Hong Liu
    Peking University People s Hospital, Peking University Institute of Hematology, Beijing, China
    Pediatr Blood Cancer 57:135-41. 2011
    ..Therefore, the impact of graft composition on transplant outcomes was evaluated...
  29. ncbi Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies
    Ying Jun Chang
    Peking University People s Hospital, Peking University Institute of Hematology, Beijing, China
    Am J Hematol 86:227-30. 2011
    ..166; 95%CI 0.037-0.750; P = 0.020). Our results suggest that a higher ALC-30 ? 300 cells/?L) could be a useful and simple tool to predict pediatric patients with a superior outcome after unmanipulated haploidentical transplantation...
  30. ncbi [Factors influencing engraftment in hematological patients after human leukocyte antigen matched sibling allogeneic blood and marrow transplantation]
    Ying Jun Chang
    Peking University People s Hospital and Peking University Institute of Hematology, Beijing 100044, China
    Zhonghua Nei Ke Za Zhi 48:647-50. 2009
    ..To investigate the factors influencing engraftment in patients with hematological diseases after human leukocyte antigen matched sibling allogeneic blood and marrow transplantation...
  31. ncbi First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate
    Yu Wang
    Peking University People s Hospital, Institute of Hematology, Beijing, People s Republic of China
    Biol Blood Marrow Transplant 15:505-11. 2009
    ....
  32. ncbi [Randomized clinical study for two types of recombinant human granulocyte colony-stimulating factor mobilizing peripheral blood and bone marrow stem cells in patients receiving allogeneic hematopoietic stem cell transplantation]
    Xiao hui Zhang
    Institute of Hematology, Peking University People s Hospital, Beijing 100044, China
    Zhonghua Yi Xue Za Zhi 89:2116-9. 2009
    ....
  33. ncbi Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma
    Xiao hui Zhang
    Institute of Hematology, Peking University People s Hospital, Beijing 100044, China
    Chin Med J (Engl) 120:463-8. 2007
    ..In this study the toxicity and efficacy of modified myeloablative conditioning regimen followed by allogeneic stem cell transplantation was investigated in patients with multiple myeloma...
  34. ncbi Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status
    Ying Jun Chang
    Peking University Institute of Hematology, Peking University People s Hospital, Beijing, China
    Biol Blood Marrow Transplant 15:632-8. 2009
    ..Our results suggest that low numbers of CD34(+) cells in allografts and advanced-stage disease may be critical factors associated with delayed platelet engraftment after unmanipulated haploidentical transplantation...
  35. ncbi Influence of lymphocyte recovery on outcome of haploidentical transplantation for hematologic malignancies
    Ying Jun Chang
    Peking University People s Hospital, Peking University Institute of Hematology, No 11 Xizhimen South Street, Beijing, China
    Medicine (Baltimore) 88:322-30. 2009
    ..211; 95% CI, 0.097-0.457; p < 0.0001). Our results suggest that the recovery of ALC-30 might have an influence on transplant outcomes following unmanipulated HLA-mismatched/haploidentical transplantation...
  36. ncbi Reconstitution of natural killer cell receptor repertoires after unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation: analyses of CD94:NKG2A and killer immunoglobulin-like receptor expression and their associations with clinical o
    Xiang Yu Zhao
    Institute of Hematology, Peking University People s Hospital, Peking University, Beijing, People s Republic of China
    Biol Blood Marrow Transplant 13:734-44. 2007
    ..Furthermore, high levels of CD94 expression in donors or in recipients by day 60 might be a good predictor for poor prognosis...
  37. ncbi [Analysis of etiology of hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation]
    Dai Hong Liu
    Institute of Hematology, People s Hospital, Peking University, Beijing 100044, China
    Zhonghua Yi Xue Za Zhi 87:124-7. 2007
    ..To analyze the etiology and clinical features of late onset hemorrhagic cystitis (LOHC) after allogeneic hematopoietic stem cell transplantation (HSCT)...
  38. ncbi Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase
    Qian Jiang
    Peking University People s Hospital, Peking University Institute of Hematology, Beijing, China
    Blood 117:3032-40. 2011
    ..All trials were registered with the Chinese Clinical Trial Registry (www.chictr.org) as CHiCTR-TNC-10000955...
  39. ncbi [Donor peripheral stem cells infusion for the treatment of failure of platelet recovery after allogeneic hematopoietic stem cell transplantation]
    Yao Chen
    Institute of Hematology, People s Hospital, Peking University, Beijing 100044, China
    Zhonghua Yi Xue Za Zhi 87:964-6. 2007
    ..To study the safety and effect of G-CSF mobilized donor hematopoietic stem cells infusion (GPBSCI) as the therapy for the failure of platelet recovery after allogeneic hematopoietic stem cell transplantation...
  40. ncbi IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation
    Xiang Yu Zhao
    Peking University People s Hospital and Peking University Institute of Haematology, Beijing, PR China
    Eur J Immunol 41:514-26. 2011
    ..Our results suggested that IL-17-producing T cells contributed to aGVHD. The application of G-CSF in vivo aided in reducing the occurrence of aGVHD through a decrease in IL-17 secretion by T cells...
  41. ncbi [The clinical analysis of nephrotic syndrome after allogeneic hematopoietic stem cell transplantation in one single center]
    Yao Chen
    Department of Hematology, Peking University People s Hospital, Beijing 100044, China
    Zhonghua Nei Ke Za Zhi 50:572-5. 2011
    ..To explore the incidence, diagnosis and treatment of nephrotic syndrome (NS) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in one single center...
  42. ncbi [Abnormal expression of programmed cell death 5 gene in multiple myeloma patients]
    Li Bao
    Peking University People Hospital, Peking University Institute of Hematology, Beijing 100044, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 18:634-7. 2010
    ..47 and 1.28 +/- 1.21 respectively (p < 0.05). It is concluded that the PDCD5 protein expression levels are low in patients with MM. These findings suggest that abnormal expression of pdcd5 may be involved in the pathogenesis of MM...
  43. ncbi [Donor lymphocyte infusion for treatment of relapse of leukemia after HLA-mismatched hematopoietic stem cell transplantation]
    Dai Hong Liu
    Institute of Hematology, People s Hospital, Peking University, Beijing 100044, China
    Zhonghua Xue Ye Xue Za Zhi 29:78-82. 2008
    ..To observe the efficacy and safety of donor lymphocyte infusion (DLI) for treatment of leukemia relapse after HLA-mismatched hematopoietic stem cell transplantation (HSCT)...
  44. ncbi Safety of recombinant human thrombopoietin in adults after related donor haploidentical haematopoietic stem cell transplantation: a pilot study
    Dai Hong Liu
    People s Hospital Peking University, Institute of Hematology, Xicheng District, Beijing, People s Republic of China
    Clin Drug Investig 31:135-41. 2011
    ..The objective of this study was to evaluate the safety of recombinant human thrombopoietin (rhTPO) administration prior to engraftment in patients who received related donor haploidentical HSCT...
  45. ncbi Positive results of serum galactomannan assays and pulmonary computed tomography predict the higher response rate of empirical antifungal therapy in patients undergoing allogeneic hematopoietic stem cell transplantation
    Yu Ji
    Institute of Hematology, Peking University, Beijing, People s Republic of China
    Biol Blood Marrow Transplant 17:759-64. 2011
    ..Thus, we concluded that serum GM assays and pulmonary CT scan could find out patients who really need empirical antifungal therapy, which resulted in improving the efficiency of the treatment...
  46. ncbi Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies
    Ying Jun Chang
    Peking University Institute of Hematology, Peking University People s Hospital, Beijing, People s Republic of China
    Biol Blood Marrow Transplant 14:323-34. 2008
    ..436; P = .059) and chronic GVHD (HR, 3.925; P = .028). Our results suggest that the recovery of NK cells is and can be used as an indicator to predicate the clinical outcomes after unmanipulated haploidentical transplantation...
  47. ncbi [A comparative study of the curative effects of cytomegalovirus preemptive therapy in various kinds of hematopoietic stem-cell transplantation]
    Xiao su Zhao
    Peking University Institute of Hematology and Peking University People s Hospital, Beijing, China
    Zhonghua Nei Ke Za Zhi 48:476-80. 2009
    ..Coherent preemptive therapy criterion was applied in various kinds of allogenic hematopoietic stem-cell transplant (allo-HSCT) recipients with cytomegalovirus (CMV) infection in order to evaluate its clinical value in various kinds of HSCT...
  48. ncbi Hemorrhagic cystitis following hematopoietic stem cell transplantation: incidence, risk factors and association with CMV reactivation and graft-versus-host disease
    Lan ping Xu
    Peking University Institute of Hematology, Peking University People s Hospital, Beijing 100044, China
    Chin Med J (Engl) 120:1666-71. 2007
    ..This study determined the incidence and risk factors for HC after allo-HSCT and analyzed its association with CMV reactivation and GVHD...
  49. ncbi [Itraconazole for treatment of fungal infections in patients undergoing allogeneic hematopoietic stem cell transplantation]
    Jing Zhi Wang
    Institute of Hematology, Peking University People s Hospital, Beijing 100044, China
    Zhonghua Nei Ke Za Zhi 46:29-31. 2007
    ..To investigate the effect of intravenous itraconazole on fungal infections in patients undergoing allogeneic hematopoietic stem cell transplantation...
  50. ncbi [Clinical features of cytomegalovirus pneumonia after allogeneic hematopoietic stem cell transplantation]
    Xiao su Zhao
    Institute of Hematology, Peking University People s Hospital, Beijing 100044, China
    Beijing Da Xue Xue Bao 41:548-53. 2009
    ..To analyze the clinical features and prognosis of cytomegalovirus (CMV) pneumonia after allogeneic hematopoietic stem-cell transplantation (allo-HSCT) under the preemptive therapy based on monitoring CMV-DNA level quantificationally...
  51. ncbi [Effect of different regimens on bone disease of multiple myeloma]
    Li Bao
    Peking University People s Hospital, Peking University Institute of Hematology, Beijing 100044, China
    Zhonghua Xue Ye Xue Za Zhi 32:221-5. 2011
    ..To explore the difference of effects of two regimens (bortezomib and dexamethasone, BD; and thalidomide and dexamethasone, TD) on bone disease in multiple myeloma (MM)...
  52. ncbi [Allogeneic stem cell transplantation for patients with Philadelphia positive leukemia resistant to imatinib]
    Wei Han
    Institute of Hematology, People s Hospital, Peking University, Beijing 100044, China
    Zhonghua Yi Xue Za Zhi 88:1974-7. 2008
    ..To investigate the effect of allogeneic hemopoietic stem cell transplantation (HSCT) in patients with acute lymphocytic leukemia (ALL) or chronic myelocytic leukemia (CML) resistant to imatinib mesylate (IM)...
  53. ncbi [The prevalence and risk factors of invasive fungal infection in hematopoietic stem cell transplant recipients]
    Lan ping Xu
    Institute of Hematology, People s Hospital, Peking University, Beijing 100044, China
    Zhonghua Nei Ke Za Zhi 46:486-9. 2007
    ..To study the incidence and risk factors of invasive fungal infection (IFI) in allogeneic hematopoietic stem cell transplant (HSCT) recipients...
  54. ncbi MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes
    Guo Rui Ruan
    Peking University People s Hospital and Institute of Hematology, 11 Xi Zhi Men South Street, Beijing 100044, China
    Hematol Oncol 28:33-9. 2010
    ..It can also provide a quantitative estimate of mutant allele burden that might be useful for both patient prognosis and monitoring response to therapy...
  55. ncbi [Detection of common fusion transcript levels in untreated leukemia patients by real-time quantitative RT-PCR technique]
    Ya Zhen Qin
    Institute of Hematology, People s Hospital of Peking University, Beijing 10004, China
    Zhonghua Xue Ye Xue Za Zhi 28:433-7. 2007
    ..To evaluate levels of common specific fusion transcripts M-bcr-abl, m-bcr-abl, TEL-AML1, AML1-ETO, PML-RAR alpha, CBF beta-MYH11 in untreated leukemia patients...
  56. ncbi [STI571 used in treating acute myeloid leukemia with Philadelphia chromosome]
    Hong Xia Shi
    Institute of Hematology, People Hospital, Peking University, Beijing 100044, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 13:88-90. 2005
    ..The case 2 died from interstitial pneumonia at 8 months after HSCT. In conclusion, STI571 is one of choice for the treatment of Philadelphia chromosome positive AML...
  57. ncbi [Quantitative analysis of dendritic cell subsets in bone marrow of patients with acute myeloid leukemia]
    Hai Rong Lin
    Institute of Hematology, People Hospital, Peking University, Beijing 100044, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 17:1249-54. 2009
    ..The percentages of patients with mDC normal or mDC increase in AML-M4/5 subtypes are more than that in AML-M2/3 subtypes, while the pDC does not show difference between AML subtypes...
  58. ncbi Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant
    Ya Zhen Qin
    Peking University Institute of Hematology, Peking University People s Hospital, Beijing, People s Republic of China
    Acta Haematol 120:146-9. 2008
    ..The vast majority of chronic myeloid leukemia (CML) patients express the BCR-ABL transcript with the b2a2 (e13a2) and/or b3a2 (e14a2) junctions. However, some rare cases have atypical breakpoints...
  59. ncbi [The efficacy and safety of mismatched hematopoietic stem cell transplantation for treatment of severe aplastic anemia]
    Wei Han
    Institute of Hematology, People s Hospital, Peking University, Beijing 100044, China
    Zhonghua Nei Ke Za Zhi 50:287-90. 2011
    ..To study the efficacy and safety of human leukocyte antigen (HLA) mismatched hematopoietic stem cell transplantation (HSCT) on severe aplastic anemia (SAA)...
  60. ncbi [Analysis of risk factors for the development of hemorrhagic cystitis post allogeneic hematopoietic stem cell transplantation]
    Hong Yu Zhang
    Institute of Hematology, People s Hospital, Peking University, Beijing 100044, China
    Zhonghua Xue Ye Xue Za Zhi 28:243-6. 2007
    ..To analyze the incidence and risk factors of hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT)...
  61. ncbi Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
    Huan Chen
    Peking University Institute of Hematology, Peking University People s Hospital, Beijing 100044, China
    Chin Med J (Engl) 124:246-52. 2011
    ..The aim of this study was to evaluate the safety and efficacy of imatinib in preventing hematological relapse when imatinib was administrated in the first 90 days after allo-HCT...
  62. ncbi [The prognostic implications of secondary chromosomal aberrations in Philadelphia chromosome-positive chronic myeloid leukemia patients after imatinib mesylate treatment]
    Yan Zhang
    Institute of Hematology, People s Hospital, Peking University, Beijing 100044, China
    Zhonghua Nei Ke Za Zhi 46:648-50. 2007
    ..To investigate the change of Philadelphia chromosome-positive clone with secondary chromosomal aberrations after imatinib mesylate (IM) treatment in patients with chronic myeloid leukemia (CML) and its relation with prognosis...
  63. ncbi [The differences between recombinant human granulocyte colony-stimulating factor-primed and non-primed peripheral blood stem cell harvests]
    Xu Liang
    Institute of Hematology, People s Hospital, Peking University, Beijing 100044, China
    Zhonghua Nei Ke Za Zhi 46:566-8. 2007
    ..To explore the differences between recombinant human granulocyte colony-stimulating factor (rhG-CSF) primed and non-primed peripheral blood stem cell harvests...
  64. ncbi [The immunophenotypic analysis of CD7+ and (or) CD56+ acute myeloid leukemic stem cells and its applications in minimal residual disease detection]
    Hui Cao
    People s Hospital of Peking University, Beijing 100044, China
    Zhonghua Xue Ye Xue Za Zhi 29:23-8. 2008
    ..To explore the immunophenotypic characteristics of CD7 and/or CD56 positive acute myeloid leukemic stem cells, and the relationship between minimal residual disease (MRD) and the leukemic stem cells (LSC)...
  65. ncbi [Transplantation of haploidentical hematopoietic stem cells from family members without in vitro T-cell depletion for treatment of hematologic malignancies in pediatric patients]
    Daihong Liu
    Peking University People s Hospital Institute of Hematology, Peking University, Beijing 100044, China
    Beijing Da Xue Xue Bao 41:291-6. 2009
    ..To evaluate the efficacy and safety of haploidentical (from family member donors) hematopoietic stem cell transplantation (HSCT) for children with hematologic malignancies...
  66. ncbi [The significance of serial monitoring of bcr-abl transcripts levels after allogeneic hematopoietic stem cell transplantation in screening chronic myeloid leukemia patients with low relapse]
    Lan ping Xu
    Peking University Institute of Hematology, Peking University People s Hospital, Beijing 100044, China
    Zhonghua Xue Ye Xue Za Zhi 29:522-5. 2008
    ..To explore dynamic status of bcr-abl transcript levels in chronic myeloid leukemia (CML) patients after allogeneic HSCT and to define low relapse patients who may not require further therapeutic intervention...
  67. ncbi [Relationship between copies of cytomegalovirus in plasma and cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation]
    Yu Hong Chen
    Hematology Institute, Peking University People s Hospital, Beijing 100044, China
    Zhonghua Yi Xue Za Zhi 89:1540-3. 2009
    ..To evaluate the clinical significance of using real-time quantitative polymerase chain reaction (RQ-PCR) in monitoring cytomegalovirus infection in allogenic hemopoietic stem-cell transplant (allo-HSCT) recipients...
  68. ncbi [A clinical study of allo-hematopoietic stem cell transplantation in HBsAg positive leukemia]
    Yao Chen
    Institute of Hematology, People s Hospital, Peking University, Beijing 100044, China
    Zhonghua Nei Ke Za Zhi 47:316-9. 2008
    ..To explore the incidence and risk factors of hepatic events and overall survival among HBsAg positive leukemia patients after allo-hematopoietic stem cell transplantation (allo-HSCT)...
  69. ncbi [Analysis of characteristics of 72 cases of t(8;21) acute myeloid leukemia]
    Yue yun Lai
    Institute of Hematology, Peking University People s Hospital, Beijing 100044, China
    Beijing Da Xue Xue Bao 37:245-8. 2005
    ..To investigate the laboratorial and clinical characteristics of t(8;21) AML, and to compare the differences between patients with additional chromosomal abnormalities and those without additional aberrations...
  70. ncbi [Pharmacokinetics of antithymocyte globulin in recipients under-going HLA partially matched hematopoietic stem cell transplantation]
    Xiao hui Zhang
    Institute of Hematology and People Hospital, Peking University, Beijing 100044, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 15:152-5. 2007
    ..There is no racial difference in the pharmacokinetics of ATG...
  71. ncbi [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease]
    Ya Zhen Qin
    Institute of Hematology, People s Hospital of Peking University, Beijing 100044, China
    Zhonghua Xue Ye Xue Za Zhi 29:441-5. 2008
    ..To investigate the expression level of preferentially expressed antigen of melanoma (PRAME) mRNA in newly diagnosed acute myeloid leukemia (AML) patients and evaluate its usefulness for detecting minimal residual disease (MRD)...
  72. ncbi [Application of ricin-immunotoxin mediated T cell depletion to allogeneic hematopoietic stem cell transplantation]
    Yue yun Lai
    Institute of Hematology, People s Hospital, Peking University, Beijing 100044, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 12:270-3. 2004
    ....
  73. ncbi Expression of CD62L on donor CD4(+) T cells in allografts: correlation with graft-versus-host disease after unmanipulated allogeneic blood and marrow transplantation
    Ying Jun Chang
    Peking University Institute of Hematology, Peking University People s Hospital, Beijing 100044, China
    J Clin Immunol 29:696-704. 2009
    ..The aim of this study was to investigate the association of donor CD4(+) T cells expressing CD62L with transplant outcomes...
  74. ncbi Expression profiles of adhesion molecules on naïve T cells in bone marrow grafts of healthy donors treated with granulocyte colony-stimulating factor
    Ying Jun Chang
    Peking University Institute of Hematology, Peking University People s Hospital, Beijing, China
    Transpl Immunol 21:228-33. 2009
    ..The aim of this study was to investigate the profiles of adhesion molecule expression on naïve T cells in bone marrow grafts of healthy donors treated with G-CSF...
  75. ncbi High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia
    Lan ping Xu
    Peking University Institute of Hematology, Peking University People s Hospital, No 11 Xizhimen, South Street, Beijing, 100044, China
    Ann Hematol 88:1015-24. 2009
    ..No other clinical parameter was influenced by graft composition. Our results suggest that a high CD4/CD8 ratio in allografts may predict adverse survival in patients with CML undergoing haplo-mismatched HSCT...
  76. ncbi [Comparative analysis of naive and memory CD4(+) and CD8(+) T-cell subsets in rhG-CSF mobilized peripheral blood and steady-state bone marrow]
    Ming Rui Huo
    Institute of Hematology and People Hospital, Peking University, Beijing 100044, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 16:605-9. 2008
    ....
  77. ncbi [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases]
    Huan Chen
    Institute of Hematology, People s Hospital, Peking University, Beijing 100044, China
    Zhonghua Yi Xue Za Zhi 88:2127-30. 2008
    ....
  78. ncbi [Investigation of plasmacytoid dendritic cell reconstitution and its relationship with cGVHD and relapse after haploidentical hematopoietic stem cell transplantation]
    Ji Ying Wu
    Institute of Hematology and People Hospital, Peking University, Beijing 100044, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 15:342-7. 2007
    ....
  79. ncbi [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation]
    Ying Jun Chang
    Peking University People s Hospital and Peking University Institute of Hematology, Beijing 100044, China
    Beijing Da Xue Xue Bao 41:208-11. 2009
    ..Further studies on the mechanism of the separation of GVL and GVHD are warranted...
  80. ncbi [Influence factors of reconstitution of killer cell immunoglobulin-like receptor on NK cells following non-T-cell-depleted haploidentical hematopoietic stem cell transplantation]
    Xiang Yu Zhao
    Peking University Institute of Hematology, People s Hospital, Beijing 100044, China
    Zhonghua Xue Ye Xue Za Zhi 28:103-6. 2007
    ..To explore the influence factors of reconstitution of killer cell immunoglobulin-like receptor (KIR) on NK cells in the early stage after non-T cells depletion (non-TCD) HLA-mismatched hematopoietic stem cell transplantation (HSCT)...
  81. ncbi [Effect of bone marrow graft collection on composition of peripheral blood stem cell grafts from healthy donors after recombinant human granulocyte colony-stimulating factor application in vivo for mobilization]
    Ying Jun Chang
    People s Hospital and Institute of Hematology, Peking University, Bejing 100044, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 16:610-3. 2008
    ....
  82. ncbi [Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic HLA mismatched/ haploidentical hematopoietic stem cell transplantation]
    Ji Ying Wu
    Institute of Hematology and People s Hospital, Peking University, Beijing 100044, China
    Zhonghua Xue Ye Xue Za Zhi 28:73-7. 2007
    ..To explore the characteristics and significance of reconstitution of peripheral blood dendritic cells (DCs) after HLA haploidentical hematopoietic stem cell transplantation (HSCT)...
  83. ncbi [Chimeric anti-CD25 monoclonal antibody for treating acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation]
    Jing Zhi Wang
    Institute of Hematology, People s Hospital, Peking University, Beijing 100044, China
    Zhonghua Nei Ke Za Zhi 47:923-5. 2008
    ..To investigate the efficacy of chimeric anti-CD(25) monoclonal antibody (basiliximab) on acute graft-versus-host disease (GVHD) in patients following allogeneic hematopoietic stem cell transplantation...
  84. ncbi [The prognostic analysis of KIR ligand mismatch in HLA-mismatched hematopoietic stem cell transplantation]
    Xiang Yu Zhao
    Institute of Hematology, People s Hospital of Peking University, Beijing 100044, China
    Zhonghua Xue Ye Xue Za Zhi 29:316-20. 2008
    ..To evaluate the prognostic implication of the killer-immunoglobulin like receptor (KIR) ligand mismatch in HLA mismatched hematopoietic stem cell transplantation (HSCT)...
  85. ncbi [CD34 cells and T cell subsets in recombinant human granulocyte colony-stimulating factor primed bone marrow grafts from donors with different characteristics]
    Ying Jun Chang
    Peking University Institute of Hematology and Peking University People s Hospital, Beijing 100044, China
    Zhonghua Xue Ye Xue Za Zhi 29:512-6. 2008
    ..To investigate the cell composition in granulocyte colony-stimulating factor One (rhG-CSF) primed bone marrow grafts (G-BM) from donors with different characteristics...
  86. ncbi [The significance of dynamic detection of WT1 expression on patients of hematologic malignancy following allogeneic hematopoietic stem cell transplantation]
    Song Jin
    Institute of Hematology, People s Hospital of Peking University, Beijing 100044, China
    Zhonghua Nei Ke Za Zhi 47:578-81. 2008
    ....
  87. ncbi [The efficacy of imatinib mesylate for 124 patients with chronic myeloid leukemia in accelerated and blastic phase]
    Qian Jiang
    Peking University, Institute of Hematology, People s Hospital, Beijing, China
    Zhonghua Xue Ye Xue Za Zhi 28:721-6. 2007
    ..To evaluate the efficacy and safety of imatinib mesylate (imatinib) for patients with Philadelphia chromosome-positive (Ph+ ) chronic myeloid leukemia (CML) in accelerated and blastic phase...
  88. ncbi Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation
    Zhi Dong Wang
    Institute of Hematology, Peking University People s Hospital, Beijing 100044, China
    Chin Med J (Engl) 123:912-6. 2010
    ..The aim of this study was to determine whether WT1 contributed to the graft-versus-leukemia effects (GVLE) for CML following allogeneic hematopoietic stem cell transplantation (HSCT)...
  89. ncbi [Combination of real-time polymerase chain reaction assay and serum galactomannan in the diagnosis of invasive aspergillosis in patients with hematological malignancies and recipients of hematopoietic stem cell transplantation]
    Yu Qian Sun
    Institute of Hematology and People s Hospital, Peking University, Beijing 100044, China
    Zhonghua Yi Xue Za Zhi 90:375-8. 2010
    ....
  90. ncbi [The value of serum galactomannan detection for diagnosis of invasive aspergillosis in hematopoietic stem cell transplant recipients]
    Yu Ji
    Institute of Hematology and People s Hospital, Peking University, Beijing 100044, China
    Zhonghua Xue Ye Xue Za Zhi 28:83-6. 2007
    ..To evaluate the value of serum galactomannan (GM) detection for diagnosis of invasive aspergillosis (IA) in hematopoietic stem cell transplant recipients...
  91. ncbi A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines
    Min Xie
    Peking University People s Hospital and Institute of Hematology, Beijing, China
    Apoptosis 14:1086-94. 2009
    ..We concluded that the triple-regulated SG611-PDCD5, as a more potent and safer antitumor therapeutic, could provide a new strategy for leukemia biotherapy...
  92. ncbi [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation]
    Lan ping Xu
    Institute of Hematology, People s Hospital, Peking University, Beijing, China
    Zhonghua Nei Ke Za Zhi 46:996-9. 2007
    ..To study the risk factors and clinical characteristics of post transplantation lymphoproliferative disorders (PTLD) after hematopoietic stem cell transplantation (HSCT)...
  93. ncbi [Secondary prophylaxis of invasive fungal infection in haematopoietic stem cell recipients]
    Lan ping Xu
    Peking University Institute of Hematology, Beijing 100044, China
    Zhonghua Nei Ke Za Zhi 48:853-6. 2009
    ..To investigate the efficacy and safety of secondary anti-fungal prophylaxis (SAP) in haematopoietic stem cell recipients who had a history of antecedent invasive fungal infection (IFI)...
  94. ncbi [Valganciclovir for treatment of cytomegalovirus viremia in patients following allogeneic hematopoietic stem cell transplantation]
    Yu Wang
    Institute of Hematology, People s Hospital of Peking University, Beijing100044, China
    Zhonghua Yi Xue Za Zhi 88:3265-7. 2008
    ..To investigate the efficacy and safety of valganciclovir in treatment of cytomegalovirus viremia in patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT)...
  95. ncbi [Differential expression levels of killer immunoglobin-like receptor genotype in patients with hematological malignancies between high-risk and standard-risk groups]
    Xiang Yu Zhao
    Peking University Institute of Hematology, Peking University People Hospital, Beijing 100044, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 16:746-9. 2008
    ..05). In conclusions, different expressions of activating KIR genes were found in patients between high-risk group and standard-risk group...
  96. ncbi [Relationship between Clostridium difficile associated diarrhea and intestinal microecosystem disorder in patients received allogeneic hematopoietic stem cell transplantation]
    Jin Song Jia
    Department of Hematolgy, Beijing University People Hospital, Beijing University Institute of Hematolgy, Beijing 100044, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 16:135-9. 2008
    ..While treating CDAD with the sensitive antibiotic, the intestinal flora of patients should be supported actively. This treatment contributes to improving disease status and reducing diarrhea recurrence...
  97. ncbi [Allogeneic hematopoietic stem cell transplantation for acute lymphocytic leukemia]
    Huan Chen
    Institute of Hematology, People's Hospital, Peking University, Beijing 100044, China
    Zhonghua Xue Ye Xue Za Zhi 25:87-90. 2004
    ..CONCLUSIONS: Allo-HSCT can cure a significant proportion of ALL patients, especially for those in CR(1). There was no significant difference in OS, DFS between the two different conditioning regimens and the different transplant choices...
  98. ncbi [Unrelated cord blood transplantation for the treatment of hematological malignancies]
    Han-yun Ren
    Institute of Hematology and People's Hospital, Peking University, Beijing 100044, China
    Zhonghua Xue Ye Xue Za Zhi 24:82-5. 2003
    ..Two units of CBT can be used for adult patients if the cell number of one unit is not enough...
  99. ncbi [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors]
    Xiao-jun Huang
    Institute of Hematology, People's Hospital, Peking University, Beijing 100044, China
    Zhonghua Yi Xue Za Zhi 83:766-9. 2003
    ....
  100. ncbi [Effects of humanized recombinant CD25 monoclonal antibody on activation and proliferation of t lymphocytes]
    Wei Liu
    Department of Hematology, The First Hospital, Peking University, Beijing 100034, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 15:134-7. 2007
    ..It is concluded that rhCD25MAb shows strong immunosuppressive activity both before and after T cell activation, suggesting that this agent may be useful in not only prophylaxis but also the treatment of acute graft-versus-host disease...
  101. ncbi [Frequency of donor TNF-alpha gene polymorphism in patients with graft versus host disease following hematopoietic stem cell transplantation]
    Jing Bo Wang
    Institute of Hematology, The People Hospital of Peking University, Beijing 100044, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 10:133-7. 2002
    ..In conclusion, the TNF-alpha-308 (G/A) is likely to contribute to high risk for III/IV degree acute GVHD and extensive chronic GVHD...